Bronchial Health: A Nutritional and Natural-Health Reference
1. Definition and Anatomical Overview
A bronchus (plural bronchi, adjective bronchial) is a passage of airway in the respiratory tract that conducts air into the lungs. The human trachea divides into two main bronchi — also called mainstem bronchi — that extend laterally, but not symmetrically, into the left and right lung respectively, at the level of the sternum. The secondary bronchi continue to branch into tertiary (segmental) bronchi, leading to even smaller airways called bronchioles. The bronchi then branch out again and become smaller and smaller passageways until they end in tiny air sacs called alveoli, which perform the important work of adding oxygen back into the blood and removing carbon dioxide.
The bronchi undergo multiple divisions — on average 23 — along the bronchial tree. The initial 16–17 generations of bronchi make up the conducting zone of the airways and do not participate in gas exchange. Their walls contain C-shaped rings of cartilage, similar to the trachea, which provide structural support and prevent collapse; as the bronchi branch into smaller airways, the amount of cartilage decreases and the proportion of smooth muscle increases.
The bronchi contain smooth muscle that contracts or dilates to control the narrowing of bronchial airways; the bronchioles rely on smooth muscle and elastic fibers to maintain their wall integrity, and these smooth muscles also secrete inflammatory mediators, making them responsible for bronchial inflammation.
2. The Bronchial Mucosal Defense System
The mucosa lining the bronchi is a sophisticated innate defense structure. The nasal cavity, trachea, and bronchi are lined by ciliated pseudostratified columnar epithelium containing goblet cells, whereas the bronchioles are lined by simple columnar or cuboidal epithelium with club (Clara) cells. The luminal surfaces of the entire conducting portion have a lining of ciliated pseudostratified columnar epithelium and contain goblet cells, whose role is to secrete mucus that serves as the first line of defense against incoming environmental pathogens.
Mucociliary clearance (MCC), also known as mucociliary transport or the mucociliary escalator, describes the self-clearing mechanism of the airways in the respiratory system. Cilia extend from the surface of bronchial epithelial cells and beat in a coordinated fashion to clear the airway lumen of excess mucus; this constant secretion and clearance of mucus is vital for several physiological functions, including airflow lubrication and the entrapment and removal of inhaled hazardous particles such as pathogens and airborne pollutants. Filtration and clearance mechanisms include nasal hairs and turbinates, which trap particulates, and the mucociliary escalator of the tracheobronchial tree, which transports inhaled material toward the oropharynx.
Mucociliary clearance, mediated by the actions of diverse conducting airway and submucosal gland epithelial cells, plays a critical role in a multilayered defense system by secreting fluids, electrolytes, antimicrobial and anti-inflammatory proteins, and mucus onto airway surfaces. Abnormalities in mucociliary clearance, whether related to impaired fluid secretion, ciliary dysfunction, lack of cough, or the disruption of epithelial cells lining the respiratory tract, contribute to the pathogenesis of common chronic pulmonary disorders. Although mucus and other airway epithelial secretions play a critical role in protecting the lung during acute injury, impaired mucus clearance after chronic mucus hyperproduction causes airway obstruction and infection, which contribute to morbidity in conditions including COPD, asthma, idiopathic pulmonary fibrosis, cystic fibrosis, bronchiectasis, and primary ciliary dyskinesia.
3. Major Conditions Affecting Bronchial Health
A range of conditions can impact the health and function of these crucial airways; these diseases often lead to symptoms such as coughing, wheezing, shortness of breath, and chest tightness.
3.1 Acute Bronchitis
Acute bronchitis is defined as a sudden inflammation of the bronchial tubes in the lung, mainly caused by viral infection, and is characterized by a persistent cough which can be productive or dry. The protracted phase of acute bronchitis involves coughing, wheezing, and sputum production and lasts from 1–3 weeks. Data from a large clinical trial revealed that the median duration of cough from acute bronchitis due to all causes was 18 days.
3.2 Chronic Bronchitis
Chronic bronchitis symptoms are defined as chronic cough and phlegm on most days for at least three months each year for at least two years. Neutrophils in the airways release neutrophil elastase, a serine protease that increases the production of mucus and stimulates the proliferation of mucus-producing goblet cells. Squamous metaplasia occurs, resulting in the replacement of many ciliated columnar epithelial cells with squamous epithelial cells. Overall, these processes of excessive bronchial mucus secretion and impaired clearance result in airway obstruction, irritation, and an increased likelihood of infection.
3.3 Asthma
Asthma is a heterogeneous disease characterized by chronic inflammation and narrowing (bronchoconstriction) of the airways, presenting with respiratory symptoms such as wheezing, shortness of breath, chest tightness, and cough. It has a complex pathophysiology consisting of airway hyper-responsiveness, eosinophilic inflammation, and ultimately airway remodeling that leads to chronic obstruction. According to the World Health Organization (WHO), asthma affects an estimated 262 million people globally.
3.4 Chronic Obstructive Pulmonary Disease (COPD)
Chronic Obstructive Pulmonary Disease (COPD), which includes chronic bronchitis and emphysema, is a progressive lung disease primarily caused by long-term exposure to irritants, leading to irreversible airflow limitation and damage to the bronchial tubes and alveoli. Airway surface dehydration and production of hyperconcentrated mucus is a common feature of chronic obstructive lung diseases such as cystic fibrosis (CF) and chronic bronchitis.
4. Contributing and Associated Factors
4.1 Tobacco Smoke and Air Pollution
Chronic bronchitis most frequently develops in tobacco smokers, approximately 30–50% of whom eventually show symptoms of this disorder. Passive exposure to smoke can also contribute to the development of chronic bronchitis. In one epidemiological study, smokers were at a significantly higher risk of chronic bronchitis, with a 2.91-times greater risk compared to nonsmokers; furthermore, exposure to secondhand smoke was associated with a significantly higher risk of chronic bronchitis, with a 5.84-times greater risk compared to non-exposure.
4.2 Occupational and Environmental Exposures
Adult chronic bronchitis is traditionally associated with smoking, occupational exposures, and lower socioeconomic status. Factors associated with the presence of chronic bronchitis symptoms include occupational exposures to dust and fumes, biomass fuels use (use of coal, coke, wood, crop residues or dung for cooking or heating), comorbid conditions including other lung diseases and heart disease, family history of chronic lung diseases, and hospitalisation for breathing problems prior to the age of 10 years.
4.3 Socioeconomic and Nutritional Status
Poor public health conditions, including malnutrition, crowding, lack of running water, and environmental pollution, increase the risk of acute lower respiratory infections and bronchitis. In affluent countries, those communities with higher prevalence of bronchiectasis are also those where poverty and low standards of housing are common.
4.4 Inflammatory and Immune Mechanisms
Viral infection stimulates the release of pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-alpha), interleukin-1beta, IL-6, and IL-18, as well as antiviral cytokines. Neutrophils are among the first cells recruited to the tracheobronchial epithelium, and their increased number correlates with the development of airway hyperresponsiveness. Oxidative stress is increased and contributes to the inflammation process in COPD patients, especially during exacerbations; reactive oxygen species generation promotes the release of mucins from epithelial cells, which can contribute to the clinical expression of the acute event.
4.5 Neural Regulation of Airway Tone
Parasympathetic fibers from the vagus nerve mediate bronchoconstriction and stimulate mucus secretion, whereas sympathetic input from thoracic nerves produces bronchodilation. Bronchoconstriction is the tightening of the smooth muscle of the bronchi from a variety of causes, which makes it more difficult to breathe.
5. Nutrients Studied in Relation to Bronchial Health
5.1 Vitamin C (Ascorbic Acid)
Mechanistic background: Oxidative stress is potentially an important pathogenic factor in the progression of bronchial asthma. Vitamin C (ascorbic acid) belongs to the most effective nutritional antioxidants. By counteracting oxidants and reducing generation of reactive oxygen species, vitamin C may inhibit external attacks in the respiratory tract, thus modulating the development of bronchial asthma.
Scientific evidence: The preventive effects of vitamin C were mediated by antioxidant, immunomodulatory, and anti-inflammatory mechanisms in experimental animal models of different respiratory diseases. In an in vitro study, vitamin C showed protective effects against hyperoxia-induced epithelial disruption; these protective effects were achieved by modulating the zona occludens-1 (ZO-1) and reducing pro-inflammatory cytokine levels. The results of another study showed that the combination of vitamin C and E can reduce the destructive effects of hyperoxia on bronchial epithelium cells by reducing oxidative damage and improving the antioxidant system.
Evidence in human populations remains preliminary and mixed. Vitamin C could affect lower respiratory tract infections; however, a study of pneumonia patients (35 cases) treated with a single-dose vitamin C for 28 days indicated that there was no association between the vitamin C treatment alone and prognosis and mortality improvement in individuals with respiratory failure and severe viral pneumonia. An increasing amount of evidence supports the notion that vitamins C, D, and E, carotenoids, and omega-3 fatty acids may protect against the progression of chronic respiratory diseases, but the authors of that 2023 PubMed literature review noted that the role of these supplements needs to be reconsidered rather than firmly established.
5.2 Vitamin D
Scientific evidence: Vitamin D deficiency has a number of biological effects that are potentially instrumental in the pathogenesis and severity of bronchial asthma. An increasing number of randomized, controlled, interventional studies show positive effects of vitamin D supplementation in pediatric and adult bronchial asthma. Vitamin D is indicated to be beneficial for the prevention and treatment of both respiratory health and mental health problems, while mental health issues are a common consequence of diseases of the respiratory system. A systematic review of randomized controlled trials noted that the studies focused on the assessment of patients with chronic obstructive pulmonary disease, increased susceptibility to respiratory tract infections, pulmonary tuberculosis, and bronchial asthma, and were conducted for various periods of time — from 2 months to a year — while the dose of vitamin D applied was diverse, from 4,000 IU applied daily to 100,000 IU applied weekly or monthly. Evidence is generally considered promising but not yet conclusive, and trial quality was variable.
5.3 Vitamin E
Evidence supports the notion that vitamins C, D, and E, carotenoids, and omega-3 fatty acids may protect against the progression of chronic respiratory diseases. In vitro and in vivo research has shown that the combination of vitamin C and vitamin E can reduce the destructive effects of hyperoxia on bronchial epithelium cells by reducing oxidative damage and improving the antioxidant system. Evidence in humans specific to vitamin E and bronchial conditions is limited to observational and combination-supplement studies; isolated vitamin E supplementation trials in bronchial health remain sparse and inconclusive.
5.4 Omega-3 Polyunsaturated Fatty Acids
Scientific evidence: The intake of omega-3 fatty acids, either through a dietary lifestyle such as the Mediterranean diet or as single nutrients, has been found to play a significant role in acute and chronic inflammatory processes. Omega-3 polyunsaturated fatty acids (PUFAs) — alpha-linolenic acid (ALA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA) — have demonstrated the ability to modulate inflammation. The main components of omega-3, DHA, and EPA, may positively impact COPD treatment by reducing inflammation. PUFA supplementation is considered beneficial in COPD; however, its effectiveness depends on factors like duration of supplementation, adherence, and comorbidities.
A notable 2023 study published in the American Journal of Respiratory and Critical Care Medicine noted that longitudinal and Mendelian randomization studies provide evidence supporting beneficial effects of higher levels of downstream omega-3 fatty acids, especially DHA, on lung health. The investigators noted that inflammation contributes to lung function decline and the development of COPD, and that omega-3 fatty acids have anti-inflammatory properties and may benefit lung health. Earlier longitudinal data presented a more cautious picture: consumption of fish has been related to lower airway hyperreactivity among children and higher lung function in adults; however, longitudinal data do not provide evidence that increased omega-3 fatty acid intake protects against lung disease. Overall, the evidence is positive and growing but still characterized by methodological heterogeneity.
5.5 Magnesium
Experimental studies of persons with asthma suggest that magnesium infusion may have a place in the acute treatment of asthma, but it does not seem to have long-term benefits based on evidence reviewed in the PubMed literature. This reflects the observation that magnesium's role in relaxing bronchial smooth muscle is mechanistically plausible, but evidence for oral supplementation in chronic bronchial conditions remains limited.
6. N-Acetylcysteine (NAC): A Nutritional Precursor with Mucolytic Activity
N-acetylcysteine is the acetylated form of the amino acid L-cysteine and a precursor to the endogenous antioxidant glutathione. It occupies a central position in both nutritional and pharmaceutical discussions of bronchial health.
Mechanism: NAC hydrolyzes the disulfide bonds of mucus proteins to decrease mucus viscosity, thereby facilitating its clearance. NAC is used as a treatment option in various conditions in which there are problems with clearance of lung mucosal secretions, such as COPD, chronic bronchitis, and in intubated or post-operative patients.
Scientific evidence — chronic bronchitis: A meta-analysis provides further evidence that patients treated with NAC have significantly and consistently fewer exacerbations of chronic bronchitis or COPD. A 2024 meta-analysis in Archivos de Bronconeumología reported that benefit in respiratory symptoms and quality of life has been shown in patients with chronic bronchitis with no documented evidence of airflow limitation, as well as in the subgroup of COPD patients; however, these results should be interpreted with caution given the variability of the tools used to assess improvement in respiratory symptoms and quality of life and the limited number of studies reporting this outcome.
Scientific evidence — acute bronchitis: A 600 mg BID dose of NAC accelerated bacterial clearance in acute bronchitis versus standard of care (70% vs. 36%; p < 0.03). A large multicenter randomized controlled trial in China involving 333 hospitalized subjects from 28 centers with respiratory diseases including acute bronchitis, chronic bronchitis and exacerbations, emphysema, mucoviscidosis, and bronchiectasis with abnormal mucus secretion evaluated IV NAC against placebo and ambroxol, and represented the first large, robust study of the efficacy of IV NAC in respiratory diseases with abnormal mucus secretion, providing new evidence for IV NAC administration in clinical situations where the IV route is preferred.
Evidence strength: For chronic bronchitis, oral NAC has moderate supporting evidence from multiple RCTs and meta-analyses. Evidence is stronger for higher doses (≥600 mg/day) and for the chronic bronchitis phenotype with mucus hypersecretion. Results for acute exacerbations of COPD are more mixed, with some trials showing no significant improvement in lung function parameters.
7. Herbs and Botanical Preparations
7.1 Thyme (Thymus vulgaris L.)
Traditional use: Thyme is a traditional Mediterranean aromatic plant used for centuries in cooking, medicine, and perfume preparations. The ESCOP monograph lists internal indications as catarrh of the upper airways, bronchitis, and supportive use for whooping cough; the German Commission E monograph lists internal indications as bronchitis, relief of whooping cough symptoms, and catarrh of the upper respiratory tract. Health Canada's Natural Health Product compendium recognizes thyme as traditionally used in herbal medicine to help relieve coughs (spasmolytic) and the symptoms of bronchitis and mucus buildup of the (upper) respiratory tract (anti-catarrh), citing the EMA 2014 assessment and multiple herbal pharmacopoeias.
Constituents: Thyme's therapeutic properties derive mainly from the essential oil, with antitussive, expectorant, antiseptic, antimicrobial, and anthelmintic properties. Effective ingredients are the essential oil with 1.5–83% thymol, the isomeric carvacrol, as well as p-cymene and gamma-terpinenes.
Scientific evidence: The EMA has published official monographs on thyme herb for respiratory use. The EMA published two monographs about the use of thyme for cough and cold, one for the herb and the second for the essential oil. In one study included in the EMA assessment report, children with bronchial catarrh or bronchitis were treated daily with 15–30 ml of thyme syrup for a period of 7–14 days. Children aged 2 months to 14 years suffering from bronchial catarrh or bronchitis were given a dose of thyme syrup over 7–14 days in an open study, with alleviation of coughing recorded in 94% of patients (European Scientific Cooperative on Phytotherapy, 2003). However, another randomized, double-blind study dealt with patients with a productive cough accompanying uncomplicated respiratory infections, comparing thyme syrup to a bromhexine preparation for 5 days, but no appreciable difference between the two interventions was reported. While these studies are rather unconvincing in terms of clinical efficacy, long-term use of Thymus spp. is supportive of the application of various products from this plant as traditional herbal remedies for the cold-accompanying productive cough. The extract of Thymus vulgaris (thyme) was found to help relax airways, suggesting it could be useful for asthma and COPD; a combination of thyme and primrose root significantly reduced bronchitis symptoms in patients with acute bronchitis and was both safe and effective.
7.2 Ivy Leaf (Hedera helix L.)
Traditional use: Hedera helix preparations (ivy leaf extracts) are worldwide marketed for the treatment of different diseases of the respiratory tract system and include catarrh of the respiratory passages, symptomatic treatment of chronic inflammatory bronchial illnesses, and acute inflammations of the respiratory tract accompanied by coughing, per the HMPC Assessment.
Mechanism: Ivy leaves (hederae helicis folium) exert an expectorant and antispasmodic action on the respiratory tract. The mode of action involves α-hederin, which inhibits the terbutaline-stimulated internalization of the beta-2 adrenergic receptor; stimulation of the beta-2 adrenergic receptor provides increased surfactant production, which leads to the liquefaction of the mucus.
Scientific evidence: The clinical effects of Hedera helix have been investigated in a total of more than 20 clinical studies, mostly in children suffering from upper airway infections. A non-interventional study assessed a cough syrup containing ivy leaf extract EA 575® by evaluating its efficacy and safety in children and adults with symptoms of acute bronchitis. One study reported that Hederae folium extract could serve as an alternative to acetylcysteine in the improvement of respiratory function in both children and adults; in both groups, alleviation of all symptoms was recorded after 7 days. A 2021 systematic review of ivy leaf for acute upper respiratory tract infections noted that one open-label RCT compared an ivy/thyme preparation to standard care: the difference in coughing fits was statistically significant at treatment days 3–4 (approximately 12 vs. 18 fits/day in treatment versus standard care groups, respectively), but not at subsequent follow-up. The body of evidence is predominantly observational and open-label; well-designed blinded RCTs with large sample sizes remain limited.
7.3 Marshmallow Root (Althaea officinalis)
The use of natural compounds or herbal drugs such as carob syrup, dry blackcurrant extract, dry extract of caraway fruit, dry extract of ginger rhizome, dry extract of marshmallow root, and dry extract of ivy leaves not only have anti-inflammatory and antioxidant activity, but also act as antimicrobials, bronchial muscle relaxants, and increase gastric motility and emptying. Marshmallow root's high mucilage content has been used traditionally to soothe the respiratory mucosa, and its traditional use for bronchial catarrh is recognized in the EMA's Community Herbal Monograph framework. Clinical evidence specific to marshmallow root in bronchial conditions remains limited; it is most frequently studied in combination products.
7.4 Honey
Traditional use: Honey has been used for many years as a traditional remedy for upper respiratory tract infection, although clear evidence for its effectiveness was initially lacking. Honey is a sweet, viscous liquid with a complex chemical composition. It is made up of a mixture of approximately 25 carbohydrates, free amino acids, vitamins, trace elements, and flavonoids, and contains compounds that function as antioxidants. Honey is said to possess antibacterial and anti-inflammatory properties.
Scientific evidence: A 2021 systematic review and meta-analysis published in BMJ Evidence-Based Medicine found that overall risk of bias was moderate, and compared to usual care, honey improved combined symptom score (3 studies; mean difference −3.96, 95% CI −5.42 to −2.51, I² = 0%), cough frequency (8 studies; SMD −0.36, 95% CI −0.50 to −0.21, I² = 0%), and cough severity (5 studies; SMD −0.44, 95% CI −0.64 to −0.25, I² = 20%). The latest systematic reviews published in 2018 and 2021 stated that honey is an effective treatment for cough and causes no severe harm; therefore, it could be used to treat acute cough. A 2014 Cochrane review of the evidence for honey to treat acute cough in children analyzed three randomised trials involving 568 children and found evidence of varying quality that honey may be better than no treatment or placebo in reducing cough frequency, possibly superior to the antihistamine diphenhydramine, and no better than the antitussive dextromethorphan. Evidence is most consistent for honey's role in symptomatic relief of upper airway cough; its effects on lower bronchial conditions specifically are less well-studied.
7.5 Other Traditionally Used Botanicals
Tulsi (also called Ocimum sanctum) is a common remedy for bronchitis and asthma in traditional Ayurvedic medicine; its key ingredient, eugenol, is associated with antimicrobial, analgesic, muscle-relaxant, and adaptogenic properties. Garlic (Allium sativum), ginger (Zingiber officinale), and licorice (Glycyrrhiza glabra) are among herbs with long traditional respiratory use across multiple cultural traditions, and they appear in several combination preparations studied for bronchial catarrh and productive cough. Natural compounds including carob syrup, dry blackcurrant extract, dry caraway fruit extract, and dry ginger rhizome extract act as antimicrobials, bronchial muscle relaxants, and increase gastric motility; these substances are widely used to control cough by contrasting its causes rather than inhibiting the cough reflex. High-quality isolate clinical trials for most of these botanicals in bronchial disease remain limited.
8. Dietary Patterns and Lifestyle Factors
8.1 Mediterranean Diet
Evidence suggests a clear link between certain dietary patterns and COPD progression. The Mediterranean diet, known for reducing the risk of respiratory diseases, stands out among effective dietary patterns; however, fast food consumption and Western eating habits are known to negatively impact COPD. Available evidence shows that the "western" diet — with high consumption of fried and processed foods, processed meats, refined sugars, and sweets — increases the risk of COPD, while a "healthy" diet rich in whole grains, vegetables, fruits, and fish is associated with better lung function. A pioneering observational study found that a Mediterranean-type dietary pattern is more likely to preserve lung function in smokers without previous respiratory disease, compared to a western diet.
8.2 Fruits, Vegetables, and Antioxidants
Consumption of fruits and vegetables with a high content of antioxidant vitamins, phenolic compounds, minerals, and dietary fiber has a positive effect on respiratory health. Longitudinal data support the hypothesis that fresh fruit consumption has a beneficial impact on the lung. Among children, consumption of fresh fruit, particularly fruit high in vitamin C, has been related to a lower prevalence of asthma symptoms and higher lung function, an effect observed even at low levels of fruit consumption (one or two servings per week versus less than one serving per week), suggesting that a small increase in dietary intake could have a beneficial effect.
8.3 Western Dietary Patterns and Processed Foods
Excessive consumption of red meat, processed meat, and sugary drinks, as well as reduced dairy intake, have been shown to worsen lung function. Conversely, a diet rich in whole grains, vegetables, fruits, and fish has been associated with a reduced risk of newly diagnosed COPD. High consumption of processed meat has been associated with worse pulmonary function and increased risk of COPD.
8.4 Smoking and Cessation
Factors favorably influencing mortality of bronchial asthma include new, more effective medications, decline in smoking, and also improved nutrition — based on awareness of the protective role of vitamins. Smoking is recognized as the single most important modifiable risk factor for chronic bronchitis and COPD. Chronic bronchitis most frequently develops in tobacco smokers, approximately 30–50% of whom eventually show symptoms of this disorder.
8.5 Mucociliary Clearance and Hydration
Airway surface dehydration and production of hyperconcentrated mucus is a common feature of chronic obstructive lung diseases such as cystic fibrosis and chronic bronchitis. Mucus hydration is driven by electrolyte transport activities, which in turn are regulated by airway epithelial purinergic receptors. Adequate systemic hydration is widely discussed in clinical practice guidelines as supporting normal mucociliary function, though large randomized trial evidence on oral hydration in isolation as a therapeutic intervention is sparse.
8.6 Physical Activity
Physical activity is recognized in respiratory medicine as positively influencing lung function and airway clearance. Dietary intake may be a major risk factor for impaired lung function, and healthy dietary habits may protect respiratory health, with lifestyle factors including physical activity typically considered alongside diet in epidemiological analyses of respiratory disease risk.
9. Summary of Evidence Strength
- N-Acetylcysteine (NAC): Moderate-to-strong evidence from multiple RCTs and meta-analyses for reducing exacerbation frequency and improving symptoms in chronic bronchitis, particularly with ≥600 mg/day dosing. Evidence for acute bronchitis is positive but thinner. Some trials show no significant improvement in objective lung function measures (FEV1).
- Ivy Leaf Extract (Hedera helix): Moderate evidence from observational and open-label studies, with EMA/HMPC traditional-use classification; RCT evidence is limited in size and blinding quality. Effects on symptom scores and coughing fits have been demonstrated.
- Thyme (Thymus vulgaris): Recognized in EMA, ESCOP, and German Commission E monographs as a traditional herbal remedy for bronchitis and respiratory catarrh. Clinical studies are mostly open-label or uncontrolled; a blinded RCT showed no difference versus bromhexine. Long history of traditional use supports safety profile.
- Honey: Growing evidence from systematic reviews and meta-analyses for symptomatic relief of cough associated with upper respiratory tract infections, with moderate overall risk of bias. Cochrane review supports use in children for acute cough (over age 1). Effect sizes are modest. Evidence pertaining specifically to lower bronchial conditions is limited.
- Vitamin C: Preliminary to moderate evidence for antioxidant protection of bronchial epithelium and modulation of airway inflammation, primarily from preclinical and in vitro studies. Human RCT evidence is inconsistent, particularly for isolated oral supplementation in chronic bronchial conditions.
- Vitamin D: Growing body of RCT evidence for benefit in asthma and reduction in respiratory infection susceptibility; evidence is promising but varies by population and dose. Systematic reviews assess quality as moderate with some concerns over bias.
- Omega-3 Fatty Acids: Longitudinal and Mendelian randomization evidence supports beneficial effects on lung function decline, particularly DHA. Dietary pattern studies (Mediterranean diet) provide consistent observational support. Isolated supplementation RCT evidence in bronchial conditions remains inconsistent.
- Mediterranean Diet Pattern: Consistent observational and epidemiological evidence for protective effects on lung function and COPD risk. Randomized trial evidence on the diet pattern as a whole in bronchial health is limited but growing.
References
- NIH/StatPearls: Anatomy, Thorax, Bronchial
- NIH/StatPearls: Anatomy, Airway
- NIH/StatPearls: Histology, Respiratory Epithelium
- Medscape: Bronchial Anatomy — Overview, Gross Anatomy, Microscopic Anatomy
- PMC/NIH: Bronchitis (Review)
- Journal of Clinical Medicine: Chronic Bronchitis in Children and Adults — Definitions, Pathophysiology, Prevalence, Risk Factors (2024)
- PMC/NIH: Prevalence and Burden of Chronic Bronchitis Symptoms — Results from the BOLD Study
- PMC/NIH: Epidemiology and Treatment of Chronic Bronchitis and Its Exacerbations
- PMC/NIH: Prevalence and Risk Factors of Patients with Chronic Bronchitis among Iraqi Adults
- PMC/NIH: Bronchiectasis and Chronic Suppurative Lung Disease
- PubMed: Airway Epithelial Differentiation and Mucociliary Clearance
- PMC/NIH: Airway Epithelial Nucleotide Release Contributes to Mucociliary Clearance
- PubMed: Deficiency of Vitamin D and Vitamin C in the Pathogenesis of Bronchial Asthma
- PMC/NIH: The Effectiveness of Supplementation with Key Vitamins, Minerals, Antioxidants, and Specific Nutritional Supplements in COPD — A Review (2023)
- PMC/NIH: The Effects of Vitamin C on Respiratory, Allergic, and Immunological Diseases — An Experimental and Clinical-Based Review
- PMC/NIH: Efficacy of Vitamin C Supplementation on COPD — A Systematic Review and Meta-Analysis
- PMC/NIH: Influence of N-Acetylcysteine on Chronic Bronchitis or COPD Exacerbations — A Meta-Analysis
- PMC/NIH: N-Acetylcysteine: A Review of Clinical Usefulness (An Old Drug with New Tricks)
- Archivos de Bronconeumología: N-Acetylcysteine Treatment in COPD and Chronic Bronchitis/Pre-COPD — Distinct Meta-Analyses (2024)
- Frontiers in Medicine: N-Acetylcysteine — Evidence-Based Consensus Document on Therapeutic Advantages in Respiratory Diseases (NECTAR, 2026)
- PubMed: Intravenous N-Acetylcysteine in Respiratory Disease with Abnormal Mucus Secretion
- PMC/NIH: Ivy Leaf (Hedera helix) for Acute Upper Respiratory Tract Infections — An Updated Systematic Review
- PMC/NIH: Assessment of the Efficacy and Safety of Ivy Leaf Cough Syrup Compared with Acetylcysteine in Adults and Children with Acute Bronchitis
- PMC/NIH: Proposed Mechanisms of Action of Herbal Drugs and Their Biologically Active Constituents in the Treatment of Coughs — An Overview
- PMC/NIH: Well-Established and Traditional Use of Vegetal Extracts as an Approach to the "Deep Roots" of Cough
- PMC/NIH: Traditional Herbal Plants and Their Phytoconstituents Based Remedies for Respiratory Diseases — A Review
- PMC/NIH: Natural Products for the Prevention and Treatment of Common Cold and Viral Respiratory Infections
- European Medicines Agency (EMA): Thymi Herba — Herbal Medicinal Product Monographs
- EMA: Assessment Report on Thymus vulgaris L.
- PMC/NIH: Honey for Acute Cough in Children — A Systematic Review (European Journal of Pediatrics, 2023)
- PubMed: Effectiveness of Honey for Symptomatic Relief in Upper Respiratory Tract Infections — A Systematic Review and Meta-Analysis (BMJ Evidence-Based Medicine, 2021)
- Cochrane Library: Honey for Acute Cough in Children (Oduwole et al., 2018)
- PMC/NIH: Omega-3 Fatty Acids and Chronic Lung Diseases — A Narrative Review of Impacts from Womb to Tomb
- American Journal of Respiratory and Critical Care Medicine: Investigating Associations of Omega-3 Fatty Acids, Lung Function Decline, and Airway Obstruction
- PMC/NIH: The Role of Nutrition and Nutritional Supplements in the Prevention and Treatment of Malnutrition in COPD — Current Approaches in Nutrition Therapy
- PubMed: Diet and Obstructive Lung Diseases
- PMC/NIH: Mediterranean Diet and Lung Function in Adult Current Smokers — A Cross-Sectional Analysis in the MEDISTAR Project
Go back